| 1 |
Trashkov AP, Gagloeva TD, Budko AI, Petrovskiy AN, Timaeva OI, Tsygan NV, Stanzhevsky AA, Vasiliev AG, Maistrenko DN, Sergunova CA, Sysoev DS, Shatic SV, Antuganov DO, Konevega AL. Anti-tumor activity of radiopharmaceutical medication based on biospecific antibodies to tumor-associated stroma elements and 177lutecium. Pediatr (SPb) 2023;13:35-44. [DOI: 10.17816/ped13635-44] [Reference Citation Analysis]
|
| 2 |
Zavvar TS, Hörmann AA, Klingler M, Summer D, Rangger C, Desrues L, Castel H, Gandolfo P, von Guggenberg E. Effects of Side Chain and Peptide Bond Modifications on the Targeting Properties of Stabilized Minigastrin Analogs. Pharmaceuticals 2023;16:278. [DOI: 10.3390/ph16020278] [Reference Citation Analysis]
|
| 3 |
Hörmann AA, Plhak E, Klingler M, Rangger C, Pfister J, Schwach G, Kvaternik H, von Guggenberg E. Automated Synthesis of 68Ga-Labeled DOTA-MGS8 and Preclinical Characterization of Cholecystokinin-2 Receptor Targeting. Molecules 2022;27:2034. [PMID: 35335396 DOI: 10.3390/molecules27062034] [Reference Citation Analysis]
|
| 4 |
Suteau V, Munier M, Ben Boubaker R, Wery M, Henrion D, Rodien P, Briet C. Identification of Dysregulated Expression of G Protein Coupled Receptors in Endocrine Tumors by Bioinformatics Analysis: Potential Drug Targets? Cells 2022;11:703. [DOI: 10.3390/cells11040703] [Reference Citation Analysis]
|
| 5 |
Fersing C, Masurier N, Rubira L, Deshayes E, Lisowski V. AAZTA-Derived Chelators for the Design of Innovative Radiopharmaceuticals with Theranostic Applications. Pharmaceuticals 2022;15:234. [DOI: 10.3390/ph15020234] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 6 |
von Guggenberg E, Kolenc P, Rottenburger C, Mikołajczak R, Hubalewska-Dydejczyk A. Update on Preclinical Development and Clinical Translation of Cholecystokinin-2 Receptor Targeting Radiopharmaceuticals. Cancers (Basel) 2021;13:5776. [PMID: 34830930 DOI: 10.3390/cancers13225776] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 7 |
Jin Y, Liu B, Younis MH, Huang G, Liu J, Cai W, Wei W. Next-Generation Molecular Imaging of Thyroid Cancer. Cancers (Basel) 2021;13:3188. [PMID: 34202358 DOI: 10.3390/cancers13133188] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 8 |
Hörmann AA, Klingler M, Rangger C, Mair C, Decristoforo C, Uprimny C, Virgolini IJ, von Guggenberg E. Radiopharmaceutical Formulation and Preclinical Testing of 68Ga-Labeled DOTA-MGS5 for the Regulatory Approval of a First Exploratory Clinical Trial. Pharmaceuticals (Basel) 2021;14:575. [PMID: 34208516 DOI: 10.3390/ph14060575] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
|
| 9 |
Corlett A, Sani MA, Van Zuylekom J, Ang CS, von Guggenberg E, Cullinane C, Blyth B, Hicks RJ, Roselt PD, Thompson PE, Hutton CA, Haskali MB. A New Turn in Peptide-Based Imaging Agents: Foldamers Afford Improved Theranostics Targeting Cholecystokinin-2 Receptor-Positive Cancer. J Med Chem 2021;64:4841-56. [PMID: 33826325 DOI: 10.1021/acs.jmedchem.0c02213] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 10 |
Hosseinimehr SJ. Radiolabeled Peptides in Imaging and Therapy: Basic and Clinical Perspectives. CMC 2020;27:6966-6967. [DOI: 10.2174/092986732741201103122538] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
|
| 11 |
Hörmann AA, Klingler M, Rezaeianpour M, Hörmann N, Gust R, Shahhosseini S, Guggenberg EV. Initial In Vitro and In Vivo Evaluation of a Novel CCK2R Targeting Peptide Analog Labeled with Lutetium-177. Molecules 2020;25:E4585. [PMID: 33049999 DOI: 10.3390/molecules25194585] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
|
